Uni-Bio Science Group Ltd
00690
Company Profile
Business description
Uni-Bio Science Group Ltd is an investment holding company. It operates in three segments: Chemical pharmaceutical products, Biological pharmaceutical products, and Pipeline products. Its geographical segments are Hong Kong and China, of which all of its revenue comes from China. The company products include GeneSoft, GeneTime, Pinup, Boshutai, Bokangtai, and others. All of the company revenue is generated from PRC.
Contact
No. 20 Science Park East Avenue
Unit 502, 5th Floor, Hong Kong Science Park
Shatin, New Territories
Hong Kong
HKGT: +852 31023232
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
487
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,643.57 | 10.58 | 0.02% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,190.52 | 92.23 | 0.44% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,383.62 | 12.76 | 0.20% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |